Clinical Trials Logo

HSIL clinical trials

View clinical trials related to HSIL.

Filter by:
  • None
  • Page 1

NCT ID: NCT06208319 Not yet recruiting - Cervical Cancer Clinical Trials

Development and Evaluation of an Artificial Intelligence Tool for Colposcopy Assistance

IACOL
Start date: March 1, 2024
Phase:
Study type: Observational [Patient Registry]

Project aiming to develop an algorithm to help the interpretation of colposcopy images, then to evaluate the effectiveness of this algorithm by using it on new cases and comparing the results obtained to the impression of expert clinicians

NCT ID: NCT03721978 Completed - Cervical Dysplasia Clinical Trials

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Start date: April 9, 2019
Phase: Phase 3
Study type: Interventional

HPV-303 is a prospective, randomized, double-blind, placebo-controlled phase 3 study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed high-grade squamous intraepithelial lesions (HSIL) (cervical intraepithelial neoplasia grade 2 [CIN2] or grade 3 [CIN3]) of the cervix, associated with HPV-16 and/or HPV-18.

NCT ID: NCT03239223 Completed - Cervical Cancer Clinical Trials

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

Start date: January 1, 2018
Phase: Phase 1
Study type: Interventional

This study evaluates the use of topical ABI-1968 cream, in the treatment of cervical precancerous lesions in adult women.

NCT ID: NCT03185013 Completed - Cervical Dysplasia Clinical Trials

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

REVEAL 1
Start date: June 28, 2017
Phase: Phase 3
Study type: Interventional

HPV-301 is a prospective, randomized, double-blind, placebo controlled Phase 3 study to determine the efficacy, safety, and tolerability of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 [CIN2] or grade 3 [CIN3]) associated with human papillomavirus (HPV) 16 and/or HPV-18.